Patents Examined by Eric S. Olson
  • Patent number: 9920137
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Grant
    Filed: July 5, 2015
    Date of Patent: March 20, 2018
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
  • Patent number: 9849146
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: December 26, 2017
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Patent number: 9849073
    Abstract: The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same.
    Type: Grant
    Filed: November 15, 2015
    Date of Patent: December 26, 2017
    Assignee: Deuteria Biomaterials, LLC
    Inventor: Glenn Prestwich
  • Patent number: 9828445
    Abstract: Synthesis of modified chitosan particles for oral insulin delivery includes amidation of chitosan with a fatty acid, a modified fatty acid, and/or an amino acid. The amidated chitosan can be grafted with N-isopropylacrylamide (NIPAm) and cross-linked to provide the modified chitosan particles.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: November 28, 2017
    Assignee: KING SAUD UNIVERSITY
    Inventors: Ayman M. Atta, Hamad A. Al-Lohedan, Abdelrahman O. Ezzat
  • Patent number: 9828633
    Abstract: Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 28, 2017
    Assignee: Pierce Biotechnology, Inc.
    Inventors: Christopher L. Etienne, Kay K. Opperman, Barbara J. Kaboord, Scott D. Meier, Jean-Samuel Schultz
  • Patent number: 9826766
    Abstract: The use of a polysaccharide in a method for improving the flora of the colon of nursing infants and/or infants, thus treating or preventing colic and enterocolitis and therefore improving and/or generally stimulating the intestinal well-being of nursing infants and/or infants. A food composition for feeding nursing infants and/or infants, including at least one polysaccharide for treating or preventing colic and enterocolitis and improving and/or stimulating the intestinal well-being of nursing infants and/or infants. The polysaccharide used is a branched maltodextrin, preferably with a molecular mass of between 400 and 4500.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 28, 2017
    Assignee: Roquette Freres
    Inventors: Laetitia Guerin-Deremaux, Virginie Teichman-Dubois, Daniel Wils
  • Patent number: 9821173
    Abstract: An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 21, 2017
    Assignee: Case Western Reserve University
    Inventor: Anthony J. Berdis
  • Patent number: 9821035
    Abstract: The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) ?-GalCer.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: November 21, 2017
    Assignee: REGIMMUNE CORPORATION
    Inventors: Omar Duramad, Hidetoshi Akimoto, Yasuyuki Ishii, Haruhiko Morita
  • Patent number: 9777074
    Abstract: This invention relates to novel compositions comprising regioselectively substituted cellulose esters. One aspect of the invention relates to processes for preparing regioselectively substituted cellulose esters from cellulose dissolved in ionic liquids. Another aspect of the invention relates to the utility of regioselectively substituted cellulose esters in applications such as protective and compensation films for liquid crystalline displays.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: October 3, 2017
    Assignee: EASTMAN CHEMICAL COMPANY
    Inventors: Charles Michael Buchanan, Norma Lindsey Buchanan, Michael Eugene Donelson, Maryna Grigorievna Gorbunova, Thauming Kuo, Bin Wang
  • Patent number: 9139572
    Abstract: The invention concerns stable nicotinamide adenine dinucleotide (NAD/NADH) and nicotinamide adenine dinucleotide phosphate (NADP/NADPH) derivatives, enzyme complexes of these derivatives and their use in biochemical detection methods and reagent matrices.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: September 22, 2015
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Joachim Hoenes, Carina Horn, Piet Herdewijn
  • Patent number: 8883986
    Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: November 11, 2014
    Assignee: Optimer Pharmaceuticals, Inc.
    Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
  • Patent number: 8853385
    Abstract: The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: October 7, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kiichiro Ueta, Kenji Arakawa, Yasuaki Matsushita
  • Patent number: 8846901
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 30, 2014
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, James D. Pipkin, Douglas B. Hecker
  • Patent number: 8841265
    Abstract: This invention provides a composition comprising a triterpenoid saponin, comprising two side groups attached to carbons 21, and 22 of the triterpenoid saponin backbone, for inhibiting skin or ovarian tumor cell growth.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: September 23, 2014
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 8841440
    Abstract: Organo-soluble chitosan salts, method for preparing organo-soluble salts, chitosan-derived materials prepared with organo-soluble chitosan salts, and methods for preparing chitosan-derived materials are disclosed.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: September 23, 2014
    Assignee: Cornell University
    Inventors: Chih-Chang Chu, Chao Zhong
  • Patent number: 8829182
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 9, 2014
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 8822432
    Abstract: A composition which can significantly accelerate equol production is provided. When formulated in a pharmaceutical preparation or a food or drink, this composition exerts effects of preventing a vascular disease by the cholesterol lowering function, preventing breast cancer or prostatic cancer, and preventing and/or treating osteoporosis. Also, when formulated in a feed or a pet food, the bone density is enhanced, so that it exerts effects to prevent weak legs of a pig, to strengthen egg shell of a laying hen, to prevent osteoporosis in a dog etc., and the like. It is a composition which comprises lactobionic acid, a salt of lactobionic acid or lactobionolactone as an active ingredient and a food or drink, a feed, a pet food or a pharmaceutical preparation, which contains the composition, and have effects to prevent and treat osteoporosis, an function to increase bone density, an effect to prevent breast cancer or prostatic cancer, and a cholesterol lowering function.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: September 2, 2014
    Assignee: Unitika Ltd.
    Inventors: Kenichi Oe, Takashi Kimura
  • Patent number: 8822705
    Abstract: The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 2, 2014
    Inventors: Je-Tae Woo, Masato Ohta, Takayuki Yonezama, Toshiaki Teruya, Byung-Yoon Cha, Kazuo Nagai, Toshihiro Akihisa, Hiroyuki Akazawa
  • Patent number: 8816067
    Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: August 26, 2014
    Assignee: Tate & Lyle Ingredients France SAS
    Inventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
  • Patent number: 8816074
    Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: August 26, 2014
    Assignee: University of Georgia Foundation, Inc.
    Inventors: Chung K. Chu, Jianing Wang